FY2025 EPS Estimates for Insmed Lifted by Cantor Fitzgerald

Insmed Incorporated (NASDAQ:INSM - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for Insmed in a research report issued to clients and investors on Monday, May 12th. Cantor Fitzgerald analyst J. Kim now anticipates that the biopharmaceutical company will post earnings of ($5.37) per share for the year, up from their prior forecast of ($5.72). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Insmed's current full-year earnings is ($4.56) per share.

A number of other equities analysts have also recently weighed in on INSM. Guggenheim reissued a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Stifel Nicolaus decreased their price target on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. Jefferies Financial Group initiated coverage on Insmed in a research note on Tuesday. They set a "buy" rating and a $105.00 price objective for the company. JPMorgan Chase & Co. upped their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Finally, Truist Financial raised their price target on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $94.63.

Insmed Trading Down 3.0%

Shares of INSM opened at $65.71 on Wednesday. The stock's 50-day moving average is $72.17 and its two-hundred day moving average is $73.26. Insmed has a 12 month low of $21.92 and a 12 month high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market cap of $11.95 billion, a PE ratio of -11.75 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same quarter in the previous year, the business posted ($1.06) EPS. Insmed's revenue was up 22.9% compared to the same quarter last year.

Institutional Investors Weigh In On Insmed

Several institutional investors have recently made changes to their positions in the company. Jennison Associates LLC lifted its position in shares of Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company's stock worth $53,424,000 after buying an additional 4,560 shares during the last quarter. Capital CS Group LLC bought a new stake in Insmed in the 4th quarter valued at $586,000. abrdn plc raised its position in Insmed by 159.5% in the fourth quarter. abrdn plc now owns 289,653 shares of the biopharmaceutical company's stock worth $19,998,000 after purchasing an additional 178,041 shares in the last quarter. Moody Aldrich Partners LLC bought a new position in shares of Insmed during the 4th quarter worth approximately $2,449,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Insmed by 14.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 37,934 shares of the biopharmaceutical company's stock valued at $2,619,000 after acquiring an additional 4,882 shares during the period.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 18,750 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $77.79, for a total value of $1,458,562.50. Following the transaction, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,996,328.94. This represents a 5.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sara Bonstein sold 18,322 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the sale, the chief financial officer now owns 118,863 shares of the company's stock, valued at approximately $9,545,887.53. This represents a 13.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 88,232 shares of company stock valued at $6,868,473. 3.00% of the stock is owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.